Citius Pharmaceuticals (NASDAQ:CTXR) Trading Down 2.4%

Citius Pharmaceuticals Inc (NASDAQ:CTXR)’s share price dropped 2.4% during trading on Tuesday . The company traded as low as $1.21 and last traded at $1.20, approximately 628,288 shares were traded during trading. A decline of 90% from the average daily volume of 6,106,217 shares. The stock had previously closed at $1.23.

CTXR has been the subject of a number of analyst reports. Zacks Investment Research cut Citius Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, July 6th. HC Wainwright reaffirmed a “buy” rating and set a $4.00 price objective on shares of Citius Pharmaceuticals in a research note on Tuesday, May 19th.

The company has a fifty day simple moving average of $1.05 and a two-hundred day simple moving average of $0.90.

Citius Pharmaceuticals (NASDAQ:CTXR) last posted its earnings results on Thursday, May 14th. The company reported ($0.13) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.03). As a group, equities analysts expect that Citius Pharmaceuticals Inc will post -0.45 EPS for the current fiscal year.

An institutional investor recently bought a new position in Citius Pharmaceuticals stock. Sabby Management LLC purchased a new stake in Citius Pharmaceuticals Inc (NASDAQ:CTXR) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 1,354,275 shares of the company’s stock, valued at approximately $813,000. Citius Pharmaceuticals makes up approximately 0.3% of Sabby Management LLC’s investment portfolio, making the stock its 12th largest holding. Sabby Management LLC owned approximately 3.56% of Citius Pharmaceuticals at the end of the most recent quarter. Hedge funds and other institutional investors own 4.73% of the company’s stock.

Citius Pharmaceuticals Company Profile (NASDAQ:CTXR)

Citius Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, and prescription products. The company develops Mino-Lok, which is in Phase III clinical trials for the treatment and salvage of infected central venous catheters in patients with catheter related bloodstream infections; and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for the treatment of hemorrhoids.

Featured Article: What is the 52-week high/low?

Receive News & Ratings for Citius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Pharmaceuticals and related companies with's FREE daily email newsletter.